When You Can't Get Your Anagrelide Filled

If you rely on Anagrelide to keep your platelet count under control and suddenly can't fill your prescription, it's understandably stressful. Essential thrombocythemia isn't something you can just put on pause — elevated platelet counts raise your risk of blood clots, stroke, and other serious events.

The good news is that Anagrelide isn't the only option. There are several proven alternatives your hematologist can consider if Anagrelide isn't available or isn't working well for you. Let's walk through them.

Important: Never switch or stop medications on your own. Always work with your hematologist or oncologist to make any treatment changes.

What Is Anagrelide and How Does It Work?

Anagrelide (brand name Agrylin) is a phosphodiesterase 3 (PDE3) inhibitor that reduces platelet production by slowing the maturation of megakaryocytes — the cells in your bone marrow responsible for making platelets. Unlike some other treatments, Anagrelide is relatively selective for platelets, meaning it doesn't significantly lower your white blood cell or red blood cell counts.

It comes as an oral capsule (0.5 mg or 1 mg) and is typically taken two to four times daily. Most patients start at a low dose and gradually increase until their platelet count reaches a safe level — generally below 600,000 cells per microliter.

For more details on the medication itself, see our complete guide: What Is Anagrelide? Uses, Dosage, and What You Need to Know.

Why Might You Need an Alternative?

There are several reasons you might need to explore other options:

• Availability issues: Anagrelide has faced intermittent shortages since Mylan discontinued production in 2015, leaving fewer generic suppliers.
• Side effects: Some patients experience significant cardiovascular side effects like palpitations, tachycardia, or fluid retention that make Anagrelide difficult to tolerate. Learn more about Anagrelide side effects.
• Insufficient response: In some cases, Anagrelide may not adequately control platelet counts despite dose adjustments.
• Contraindications: Patients with serious heart conditions, QT prolongation, or severe liver disease may not be good candidates for Anagrelide.

Alternative #1: Hydroxyurea

Hydroxyurea (brand names Hydrea, Droxia) is the most commonly prescribed first-line treatment for essential thrombocythemia. In fact, many treatment guidelines recommend Hydroxyurea before Anagrelide for high-risk patients.

How it works: Hydroxyurea is an antimetabolite that suppresses bone marrow production more broadly. It reduces platelet counts, but also lowers white blood cell and red blood cell counts, which means it requires close monitoring with regular blood tests.

Key facts:

• Available as oral capsules (200 mg, 300 mg, 400 mg, 500 mg)
• Typically taken once daily
• Generic versions are widely available and affordable (often under $20/month with coupons)
• Well-studied in large clinical trials (the PT-1 study showed Hydroxyurea plus aspirin was superior to Anagrelide plus aspirin for high-risk ET patients)
• Can cause myelosuppression — your doctor will monitor your blood counts closely

Who it's good for: Most patients with essential thrombocythemia, especially those at high risk for thrombotic events. It's widely available and inexpensive.

Alternative #2: Pegylated Interferon Alfa-2a (Pegasys)

Pegylated Interferon Alfa-2a (Pegasys) is an injectable medication increasingly used for essential thrombocythemia, particularly in younger patients.

How it works: Interferon modulates the immune system and has been shown to reduce the abnormal clone of cells that drives myeloproliferative neoplasms. It may have disease-modifying potential — meaning it could actually address the underlying cause, not just the symptoms.

Key facts:

• Given as a subcutaneous injection, typically once weekly
• May achieve molecular responses (reducing the JAK2 mutation burden)
• Common side effects include flu-like symptoms, fatigue, and mood changes
• Generally preferred for younger patients, women planning pregnancy, and those seeking disease modification
• More expensive than Hydroxyurea; insurance coverage varies

Who it's good for: Younger patients, those who want to avoid the long-term risks of Hydroxyurea, patients with a JAK2 mutation who may benefit from disease modification, and women of childbearing age (though it should be stopped before conception).

Alternative #3: Ruxolitinib (Jakafi)

Ruxolitinib (brand name Jakafi) is a JAK1/JAK2 inhibitor that's FDA-approved for myelofibrosis and polycythemia vera. It's used off-label for essential thrombocythemia in patients who don't respond to other treatments.

Key facts:

• Oral tablet taken twice daily
• Primarily targets the JAK-STAT signaling pathway, which is often overactive in myeloproliferative neoplasms
• Can reduce platelet counts, spleen size, and constitutional symptoms
• Expensive — retail price can exceed $15,000/month without insurance
• Insurance coverage for off-label ET use may be difficult to obtain

Who it's good for: Patients with ET who have failed or can't tolerate Hydroxyurea and Anagrelide, particularly those with significant symptom burden or splenomegaly.

Alternative #4: Busulfan

Busulfan is an alkylating agent that's been used for decades to treat myeloproliferative neoplasms. It's typically reserved as a second or third-line option.

Key facts:

• Oral tablet
• Effective at reducing platelet counts
• Carries a risk of leukemic transformation with long-term use, so it's generally reserved for older patients or those who can't tolerate other options
• Requires careful monitoring

Who it's good for: Older patients who have not responded to or cannot tolerate Hydroxyurea, Anagrelide, or Interferon.

How to Talk to Your Doctor About Alternatives

If you're considering a switch from Anagrelide, here's what to bring up with your hematologist:

• Why you need an alternative (availability, side effects, or inadequate response)
• Your risk profile — age, JAK2 mutation status, history of blood clots
• Your preferences — oral vs. injectable, side effect concerns, cost
• Whether the switch is temporary (waiting for Anagrelide to become available) or permanent

Your doctor can help weigh the pros and cons of each option based on your specific situation.

Final Thoughts

Losing access to a medication you depend on is scary, but you're not without options. Hydroxyurea is widely available and well-studied. Pegylated Interferon offers disease-modifying potential. And for more complex cases, Ruxolitinib and Busulfan provide additional pathways.

If you haven't exhausted your options for finding Anagrelide itself, start with Medfinder to check local pharmacy availability, or read our guide on how to find Anagrelide in stock near you. And if cost is part of the equation, explore ways to save money on Anagrelide.

Whatever path you take, work closely with your hematologist to make sure your platelet count stays under control and your treatment stays on track.